Richard Lutz
Clinical Genetics (M.D.) · Omaha, NENPI 1992755326
Payments from drug & device makers
Across 48 payments — averaging $10,324 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$322K
- Shire North American Group Inc$173K
- Biomarin Pharmaceutical Inc.$164
- CSL Behring$62
- Amgen$24
- Amicus Therapeutics, Inc.$16
- plus $10 from 1 others
What the payments were for
- Food & beverage$30597%
- Education$103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $322,489 |
| Shire North American Group Inc | 5 | $172,803 |
| Biomarin Pharmaceutical Inc. | 7 | $164 |
| CSL Behring | 1 | $62 |
| Amgen | 1 | $24 |
| Amicus Therapeutics, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 3 | $10 |
How this compares
Too few clinical genetics (m.d.) providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Omaha
- William RizzoOmaha$170K
- Craig BakerOmaha$945
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.